Yes: the HHS policy document describes an interim 503A peptide list of six peptides—BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500. The document describes a narrow, conditional proposed enforcement-discretion pathway for qualifying 503A compounding while a final rule considers each substance; it does not make the peptides FDA-approved or remove the policy’s route, sourcing, prescription, reporting, and formulation limits. Confirm that the policy has been issued and is effective before treating that pathway as available.
October 28, 2026

Six listed peptides; one policy pathway; route-specific limits. A favorable Pharmacy Compounding Advisory Committee vote did not itself place any peptide on the final 503A bulks list.
Which peptides are on the HHS 503A list?
HHS lists these six broader peptide names in Appendix A of its 503A peptide enforcement policy. Appendix B identifies the specific covered form and route a compounder may use.
| Peptide | Appendix B route limit | PCAC vote | CDER recommendation | What HHS said changed | What remains unresolved |
|---|---|---|---|---|---|
| BPC-157 acetate | Subcutaneous, intramuscular, oral, or topical | Voted for inclusion | Recommended against listing | HHS cited documented historical use, multiple human studies, and lot-specific testing records. | Its final 503A bulks-list outcome and whether a particular product meets every policy condition. |
| Epitalon acetate | Subcutaneous or intramuscular injection, in intermittent courses | Voted for inclusion | Recommended against listing | HHS cited added lot testing, documented historical use, limited controlled human exposure with no reported side effects, and intermittent regimens. | Its final list outcome and the details of any qualifying compounded prescription. |
| KPV acetate | Topical or oral only | Voted for inclusion | Recommended against listing | HHS cited documented historical use, including substantial single-ingredient use, plus mass-spectrometry, endotoxin, and microbial results. | Its final list outcome and whether an oral formulation has the required human oral-bioavailability documentation. |
| MOTS-c acetate | Subcutaneous or intramuscular injection | Voted for inclusion | Recommended against listing | HHS cited expanded lot-specific quality records, documented historical use, and a randomized placebo-controlled trial of a MOTS-c analogue that reported no serious adverse events. | Its final list outcome and whether a specific compounded product meets the policy. |
| Semax free base | Intranasal only | Voted for inclusion | Recommended against listing | HHS cited certificates addressing the endotoxin issue for injectable use, additional chemistry records, historical-use information, and an intranasal human record covering several hundred subjects with no reported adverse outcome. | Its final list outcome; injectable Semax is outside this policy route limit. |
| TB-500 acetate | Subcutaneous or intramuscular injection | Voted for inclusion | Recommended against listing | HHS cited lot-specific quality records, documented historical use, and its view that the cited safety concerns were inferential rather than observed. | Its final list outcome and whether a particular injectable product satisfies all safeguards. |
For all six, HHS says they were in FDA Category 2 from September 2023 until April 22, 2026. The committee’s votes were advisory; the final bulks-list decision still comes through rulemaking.
What does the HHS policy actually change?
The HHS policy document states that, until a final rule addresses a listed peptide, HHS does not intend to take action against a state-licensed pharmacy, federal facility, or licensed physician compounding it when every condition in the policy is met. The OIRA review record had no publication date as of October 28, 2026, so the policy’s issuance and effective status should be confirmed before relying on it. That is enforcement discretion, not FDA approval. The FDA explains that its January 2025 503A interim policy concerns compounding while the agency develops the bulk-substances list, and the FDA guidance identifies it as a compounding policy.
The practical point is simple: a peptide’s name on this HHS list is only the first gate. The route, ingredient identity, prescription, source, product design, labeling, and reporting requirements must all line up.
What must be true for the policy to apply?
- You need a valid patient-specific prescription.
- The exact peptide identity and route must match Appendix B.
- The original manufacturer of the bulk substance must be FDA-registered, comply with CGMP and other FD&C requirements, and have its facility location listed on a valid certificate of analysis. If the substance comes through an FDA-registered repacker, relabeler, or reseller, that entity must document vendor validation of the manufacturer and validation of the manufacturer’s certificate of analysis.
- The compounded product may contain only one API, and that API must be listed in Appendix A. Combination vials containing two or more peptides are outside the policy.
- Compounders must report products, serious adverse events, and quality problems to FDA MedWatch and the relevant states.
- The label must say: “This is a compounded drug product. Not for resale.”
- If a delivery device is included, it may only be an FDA 510(k)-cleared syringe.
- For an oral product, the compounder must document adequate oral bioavailability in humans for that specific formulation.
Section 503A generally requires compounding for an identified patient based on a valid prescription, while allowing limited anticipatory compounding under specified conditions; it also sets requirements for registered bulk-substance manufacturers and valid certificates of analysis; see 21 U.S. Code § 353a. HHS also says compounded drugs are not FDA-approved, meaning FDA does not review their safety, effectiveness, or quality before marketing.
Are these peptides legal in the United States?
The HHS policy document describes a conditional pathway for the six listed peptides when all listed conditions are met, but readers and pharmacies should confirm that it has been issued and is effective before relying on it. A research-use-only vial is not covered, and neither are GHK-Cu, a peptide outside Appendix A, a multi-peptide vial, or a route outside that peptide’s Appendix B limit.
HHS says the policy is intended in part to discourage use of research-use-only peptides supplied by foreign manufacturers. If you are deciding between a prescriber working with a licensed 503A pharmacy, an FDA-approved peptide drug, or waiting for the final rule, do not treat a research-use-only listing as the same option. For a separate overview, see what peptides are FDA approved.
Are the six peptides proven to work or safe?
This policy is not a finding that a particular peptide product works for a particular purpose. It is a regulatory enforcement policy with conditions designed around access, traceability, quality records, route limits, single-API products, and reporting.
HHS does describe one specific study detail for MOTS-c: a randomized, placebo-controlled trial of a MOTS-c analogue reported no serious adverse events at exposure HHS described as well above the compounded regimen. For Semax, HHS describes an intranasal human record covering several hundred subjects with no reported adverse outcome. Those statements are part of HHS’s justification for this interim policy, not approval of a finished compounded product.
FDA’s category page says Category 2 substances were identified as potentially presenting significant safety risks during FDA’s review of nominations. You can read that regulatory context on FDA’s bulk-substance risk page. HHS may revisit this interim policy if a safety signal or product-quality issue arises.
What did the committee vote, and what did CDER recommend?
For each of the six peptides, HHS says CDER recommended against listing it and the Pharmacy Compounding Advisory Committee voted in favor of inclusion. The July vote produced a nonbinding advisory recommendation; it did not itself add a peptide to the final 503A bulks list.
OIRA completed review of “Interim Access Policy for Compounding Using Certain Peptides” on October 27, 2026, with the conclusion “Consistent with Change,” according to the OIRA review record. As of October 28, 2026, the OIRA record shows no publication date for the policy.
What about celebrity peptide lists or the “top three” peptides?
This is not a ranking of peptides to take, a list of celebrity routines, or a guide to building muscle. It also does not select a “big three” or a best peptide for any goal; it defines a temporary, route-limited compounding policy for six named bulk drug substances.
If you are trying to understand the wider category rather than this policy, exploring peptides explains the types and uses people commonly encounter. For general nutrition context, visit supplements and everyday wellness.
Before you act on the HHS list
- Confirm the exact peptide form and route against Appendix B; route is not interchangeable.
- Ask whether the pharmacy is operating under the policy’s patient-specific prescription, single-API, sourcing, certificate-of-analysis, labeling, and reporting conditions.
- For an oral listed peptide, ask whether the pharmacy has documentation for adequate human oral bioavailability of that specific formulation.
- Do not equate the policy with FDA approval or a final 503A bulks-list decision.
- For a medication decision, discuss your individual circumstances with your clinician.
By the Clinical Research Explained Editorial Team
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.